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http://dx.doi.org/10.1016/j.ccr.2012.11.019SUMMARYThe progression of cancer to metastatic disease is a major cause of death. We identifiedmiR-708 being tran-
scriptionally repressed by polycomb repressor complex 2-induced H3K27 trimethylation inmetastatic breast
cancer.miR-708 targets the endoplasmic reticulumprotein neuronatin to decrease intracellular calcium level,
resulting in reduction of activation of ERK and FAK, decreased cell migration, and impaired metastases.
Ectopic expression of neuronatin refractory to suppression by miR-708 rescued cell migration and metas-
tasis defects. In patients with breast cancer, miR-708 expression was decreased in lymph node and distal
metastases, suggesting a metastasis-suppressive role. Our findings uncover a mechanistic role for miR-
708 in metastasis and provide a rationale for developing miR-708 as a therapeutic agent against metastatic
breast cancer.INTRODUCTION
Malignant primary tumor cells colonize distal organs to form
metastases resulting in more than 90% of cancer-related deaths
(Gupta and Massague´, 2006; Steeg, 2006). Many studies have
investigated cancer cell intrinsic mechanisms and the extrinsic
microenvironmental factors that enhance the metastatic poten-
tial of primary tumor cells (Fidler, 2003; Gupta and Massague´,
2006; Joyce and Pollard, 2009). The metastatic cascade
comprises a series of steps to accomplish invasion, migration,
dissemination, and colonization of target organs to generate
lethal metastases. However, our understanding of the regulators
that mediate the metastatic cascade has remained incomplete.
MicroRNAs (miRNAs) are small, noncoding RNAs (18–23
nucleotides in size) that regulate gene expression bySignificance
Patients with triple-negative breast cancer (TNBC) have the wo
propensity for recurrence andmetastatic spread. Furthermore,
treatment of TNBC. Here, we show that the expression of m
cancer. We demonstrate that polycomb repressor complex 2
neuronatin, which elevates intracellular Ca2+ levels to promot
findings support the notion that miR-708 is a potential therapesequence-specific binding to messenger RNA (mRNA) and
trigger translation repression or RNA degradation (Bartel,
2004). miRNAs play important roles in various biological
processes, including cell growth, differentiation, and develop-
ment (Alvarez-Garcia and Miska, 2005; Inui et al., 2010).
Abnormal miRNA expression has been reported in various
diseases including cancer (Calin and Croce, 2006; Lu et al.,
2005; Ozen et al., 2008; Volinia et al., 2006). More than 50% of
miRNA-encoding loci reside in chromosomal regions altered
during tumorigenesis (Calin et al., 2004), and expression profiling
reveals characteristic miRNA signatures for many tumor types,
including breast neoplasia, that predict disease status and
clinical outcome (Calin and Croce, 2006). In addition, miRNAs
have been identified that function as oncogenes or tumor
suppressor genes (Magalhaes et al., 2002; Ventura et al., 2008),rst outcome among patients with breast cancer due to high
to our knowledge, there is no approved targeted therapy for
iR-708 is reduced during metastatic progression of breast
-mediated suppression of miR-708 increases expression of
e cell migration and metastasis formation. Together, these
utic against metastatic breast cancer.
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Figure 1. miR-708 Is Downregulated in Metastatic Cancer Cells and Affects Cell Migration
(A) Heatmap obtained from high-throughput miR-seq profiling of nontumorigenic breast epithelial cells (MCF-10A, lane 1) and nonmetastatic (Non-met) (MCF7,
lane 2) and metastatic breast cancer cell lines (MDA, lanes 3 and 4; LM2, lanes 5 and 6). Each row represents a miRNA that is differentially regulated (2-fold or
more in sequence-read frequencies), and each column represents the average of two biological replicates. The relatively high expression is indicated in red,
whereas the relatively low expression is in green.
(B) Quantitative RT-PCR analysis of miR-708 in a panel of nontumorigenic and tumorigenic (nonmetastatic and metastatic) breast cells. miR-708 expression
analysis was performed in triplicate and normalized to the internal control, RNU48. y Axis depicts fold change in miR-708. Data represent mean ± SD.
(C) Microscopy images showing miR-708 in situ hybridization (red) in nonmetastatic MCF-7 cells (MCF7, top) and metastatic MDA (bottom) breast cancer cells.
Scale bars, 50 mm.
(D) In situ hybridization of miR-708 (red) in GFP+ primary breast tumors (Primary tumor) and lung metastases (Lung Met) in MMTV-PyMT;WAP-Cre;CAG-CAT-
EGFPmice. Dotted line indicates primary tumor (green) in mammary gland and metastatic lesion (green) in the lung. DAPI was used to label the nuclei of all cells.
Scale bars, 50 mm.
(legend continued on next page)
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miR-708 Is a Suppressor of Metastasisand some act at late stages of tumor progression (Ma et al., 2007;
Tavazoie et al., 2008; Ventura et al., 2008; Huang et al., 2008;
Asangani et al., 2008; Zhu et al., 2008; Lujambio et al., 2008).
Recent studies have identified miRNAs that contribute to the
pathophysiology of breast cancer via mechanisms enabling
invasion and metastasis (Huang et al., 2008; Iorio et al., 2005;
Ma et al., 2007; Valastyan et al., 2009), epithelial-to-mesen-
chymal transition (Bracken et al., 2009; Gregory et al., 2008),
and maintenance of breast stem cells (Shimono et al., 2009).
Despite these studies, the role of miRNAs in specifically
affecting the later steps in the metastatic cascade without
confounding influences on primary tumor development has re-
mained unclear (Ma et al., 2007; Valastyan et al., 2009; Valastyan
and Weinberg, 2009). From a clinical translation perspective,
whereas blocking primary tumor invasion and dissemination is
considered an effective approach in blocking metastasis, an
important question is how best to treat patients whose tumor
has already metastasized. Thus, approaches are required to
block widespread tumor dissemination and outgrowth in
secondary organs for effective treatment of metastatic breast
cancer. Considering the emerging roles of miRNAs in cancer
biology, we set out to identify miRNAs that impact metastasis
without affecting primary tumor growth and addressed its under-
lying molecular mechanisms and therapeutic potential against
metastatic breast cancer.
RESULTS AND DISCUSSION
Identification of Differentially Regulated miRNAs
in Metastasis
To identify miRNAs that regulate the metastatic cascade without
affecting primary tumor growth, we performed next-generation
miRNA sequencing (miR-seq) on human breast epithelial cell
lines with different tumorigenic and metastatic potentials (Kang
et al., 2009; Minn et al., 2005) (Table S1 available online). Total
RNA was processed to generate libraries for miR-seq, and
sequence reads obtained from each breast cancer cell line in
duplicate were used for identifying miRNAs as described (Ryu
et al., 2011). Alignment of sequence reads to known miRNA
sequences in the miRNA database (miRBase v.16) revealed
80% of reads that matched known human miRNAs (Table
S2). Hierarchical clustering analysis revealed groups of differen-
tially regulated miRNAs (Figure 1A), and miRNAs that were up-
and downregulated in metastatic tumor cells were identified(E) Representative images depicting a cell migration assay performed with 1 3 1
were plated into 6-well dishes and allowed to grow for 12 hr, after which a scratch
200 mm.
(F) Cell migration was quantified as percentage of wound-healed area. Data re
experiments.
(G) Upper panel is a schematic of a lentiviral vector expressing miRNA ‘‘sponge
promoter; P-I-C, puromycin-IRES-CFP; LTR, long-terminal repeat and sponge (1
fold change inmiR-708 expression levels in MCF7 cells stably expressing the miR
(MDA). Data represent mean ± SD.
(H) Representative images depicting a cell migration assay performed with 1 3 1
were plated into 6-well dishes and allowed to grow for 12 hr, after which a scratc
200 mm.
(I) Cell migration was quantitated as percentage of wound-healed area fromMCF7
mean ± SD of nine randomly selected areas from three independent experiment
See also Tables S1–S4 and Figure S1.(Tables S3 and S4). As expected, we also identified previously
discovered metastatic miRNAs including miR-200 family,
miR-10, andmiR-196 (Valastyan andWeinberg, 2009), validating
our miRNA-profiling approach.
miR-708 Is Downregulated in Metastatic Tumor Cells
Both In Vitro and In Vivo
From the list of differentially regulated miRNAs, we focused on
miR-708 because it was one of themost downregulated miRNAs
in metastatic tumor cells. Although miR-708 is highly conserved
across species (Figure S1A), its role in tumor metastasis is
unclear. Analysis of miR-708 expression levels in a panel of
human breast cancer cell lines showed that miR-708 was mark-
edly suppressed in metastatic cells compared with tumorigenic
but nonmetastatic cells (Figure 1B). In agreement with RT-PCR
analysis, in situ hybridization with a miR-708-locked nucleic
acid (LNA) probe showed abundant miR-708 expression in non-
metastatic MCF7 cells, compared with metastatic MDA-MB-231
(MDA) cells (Figure 1C). Further analysis showed lower levels of
miR-708 in basal subtype breast cancer cell lines compared to
luminal subtype (Figure S1B). Consistent with cell lines, basal/
triple-negative breast cancer (TNBC) subtype of human breast
cancers had lower levels of miR-708 compared to the luminal
subtype (Figure S1C). To evaluate miR-708 expression in spon-
taneousmetastaticmammary tumors, we used theMMTV-PyMT
mousemodel, which develops primary breast tumors (6–7weeks
of age) that progress and give rise to metastases in the lungs
(12–16 weeks of age) (Guy et al., 1992; Gao et al., 2008; Nolan
et al., 2007). To reliably detect tumor cells at both the primary
sites and in the metastatic organs, we used the MMTV-PyMT;
WAP-Cre;CAG-CAT-EGFP mice that express GFP in mammary
tumor cells (Ahmed et al., 2002), thus enabling the analysis of
GFP-tagged primary tumors and matched pulmonary metas-
tases in immunocompetent mice. In situ hybridization with the
miR-708 LNA probe showed miR-708 expression in GFP+
primary breast tumors, as expected. However, the GFP+ pulmo-
nary metastases were devoid of miR-708 expression (Figures 1D
and S1D), an observation further confirmed by RT-PCR analysis
of several excised primary tumors andmatchedmetastases (Fig-
ure S1E). As a control, expression of ubiquitously expressing U6
snRNA remained unchanged (Figure S1E).
Having demonstrated suppression of miR-708 expression in
metastatic cancer cells, we sought to evaluate the antimetastatic
role of miR-708. A lentiviral delivery system (Ryu et al., 2011) was06 MDA control (Control) and MDA expressing miR-708 (miR-708) cells. Cells
was created, and cells were imaged immediately (0 hr) and at 36 hr. Scale bars,
present mean ± SD of nine randomly selected areas from three independent
.’’ EF1a, elongation factor 1 a promoter; PGK, phosphoglycerate kinase gene
2XU); 12 miR-708 binding sites. Lower panel is a quantitative RT-PCR showing
-708 sponge compared with MCF7 (MCF7-miR-708 sponge) andMDA controls
06 MCF7 control (Control) and MCF7 ‘‘sponge’’ (miR-708 sponge) cells. Cells
h was created, and cells were imaged immediately (0 hr) and 60 hr. Scale bars,
control (Control) and MCF7 ‘‘sponge’’ (miR-708 sponge) cells. Data represent
s.
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Figure 2. miR-708 Expression Attenuates
Metastasis In Vivo
(A) Representative bioluminescence (BLI) images
of animals showing primary tumors (PT) at day 60
derived from orthotopic injections into the
mammary fat pad of MDA vector control (Ctrl) and
MDA expressing miR-708 (miR-708) cells. The
color scale bar depicts the photon flux (photons
per second) emitted from these mice.
(B) Quantitation of primary tumors as assessed by
BLImeasurements (day 60, n = 10 per group). Data
represent mean ± SD.
(C) Representative BLI of animals from (A) showing
lung metastases (MET) at day 74. In this case,
primary tumors were resected at day 60. The color
scale bar depicts the photon flux (photons per
second) emitted from these mice.
(D) Quantitation of pulmonary metastases as as-
sessed by BLI measurements (day 74, n = 10 per
group). Data represent mean ± SD.
(E) Representative BLI of animals showing lung
metastases derived from orthotopic injections
into the mammary fat pad of LM2 vector control
(Ctrl) and MDA-MB-231-LM2-miR-708 (miR-708)
cells at day 67. Primary tumors were resected
at day 60. The color scale bar depicts the photon
flux (photons per second) emitted from these
mice.
(F) Quantitation of pulmonary metastases as as-
sessed by BLI measurements (day 67, n = 10 per
group). Data represent mean ± SD.
(G) Schematic of a lentiviral vector used for
inducible expression and representative images of
miR-708 following doxycycline (Dox) administra-
tion by food (200 mg/kg). Scale bars, 50 mm.
(H) Quantitative RT-PCR showing miR-708
expression levels in the presence of Dox (+Dox)
or absence of Dox (Dox). Data represent
mean ± SD.
(I) Representative BLI of animals with primary tumors generated following orthotopic injections of MDA-MB-231-miR-708 in the mammary glands of SCIDmice in
the presence of Dox (+Dox) or absence of Dox (Dox) at day 60.
(J) Quantitation of primary tumors as assessed by BLI measurements (day 60, n = 10 per group). Data represent mean ± SD.
(K) Representative BLI of animals showing lung metastases from (I) in the presence of Dox (+Dox) or absence of Dox (Dox) (day 74). The primary tumors were
resected at day 60.
(L) Quantitation of pulmonary metastases assessed by BLI measurements (day 67, n = 10 per group). Data represent mean ± SD.
See also Figure S2.
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miR-708 Is a Suppressor of Metastasisused to stably express miR-708 in metastatic human breast
tumor cell lines MDA andMDA-MB-231-LM2 (LM2) (Figure S1F).
MDA cells stably expressing miR-708 exhibited suppressed
migration rates compared with controls (Figures 1E and 1F) but
no significant change in cell proliferation (Figure S1G). Consistent
with observations in breast cancer, ectopic expression of miR-
708 also suppressed migration of metastatic prostate cancer
cell PC3 (Figure S1H). Having observed that overexpression of
miR-708 in metastatic breast cancer cells inhibited migration,
we asked whether inhibiting miR-708 in nonmetastatic breast
cancer cells might stimulate migration. To address this, we con-
structed a lentiviral vector expressing a miRNA-708 ‘‘sponge,’’
a strategy that has previously been used for miRNA blockade
(Ebert et al., 2007; Valastyan et al., 2009), to suppress miR-708
expression (Figure 1G). As expected, the ‘‘miR-708 sponge’’
inhibited miR-708 expression by >2-fold (Figure 1G), and miR-
708 loss of function enhanced migration rates of MCF7 cells
(Figures 1H and 1I). These results demonstrate that metastatic66 Cancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc.breast cancer cells exhibit lower levels of miR-708, and ectopic
expression of miR-708 attenuates cell migration. In contrast,
nonmetastatic breast cancer cells exhibit higher levels of miR-
708, and suppression of miR-708 enhances cell migration.
miR-708 Expression Impairs the Formation
of Metastases
To explore whether enhanced migration conferred a metastatic
advantage to breast cancer cells in vivo, we injected MDA cells
stably expressing miR-708 and a luciferase reporter transgene
orthotopically into the mammary fat pad of mice. Biolumines-
cence imaging (BLI) showed no significant difference in the
primary tumor growth but a significant reduction in lung metas-
tases as a result of miR-708 expression (Figures 2A–2D). We
confirmed the antimetastatic role of miR-708 in LM2. Consistent
with previous observations, primary tumor growth in LM2 over-
expressing miR-708 remained unperturbed; however, there
was a pronounced reduction in lung metastases (Figures 2E,
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miR-708 Is a Suppressor of Metastasis2F, S2A, and S2B). To exclude the remote possibility that consti-
tutive expression of miR-708 during the establishment of stable
breast cancer cells could have inadvertently conferred an anti-
metastatic phenotype, a doxycycline-based conditional expres-
sion of miR-708 was used (Gao et al., 2008; Stegmeier et al.,
2005). This approach allowed us to generate acute miR-708
expression only after the cells were administered in vivo. miR-
708 was cloned into a doxycycline-inducible vector, and the
specific and tight regulation of miR-708 expression by the induc-
ible system was assessed in vitro (Figures 2G and 2H). Adminis-
tration of these cells into the mammary fat pad of SCID mice
followed by doxycycline-mediated induction of miR-708 did
not affect primary tumor growth (Figures 2I and 2J) but attenu-
ated metastases (Figures 2K and 2L), consistent with results
using the constitutive system. Although miR-708 loss of function
enhanced migration rates in the MCF7 model, it was not suffi-
cient to promote metastasis in vivo (data not shown), suggesting
that the MCF7 cells may need additional prometastatic proper-
ties to accomplish successful metastasis. Taken together, these
results demonstrate that expression of miR-708 in metastatic
breast cancer cells attenuates metastasis formation in vivo but
did not impact primary tumor growth, which provided an oppor-
tunity to determine its role in the later steps of metastatic
progression.
miR-708 Suppresses Expression of Neuronatin,
a Regulator of Intracellular Calcium
To identify downstream effectors of miR-708, we used mRNA
target-predicting algorithms (TargetScan, miRanda, and Targe-
tRank) based on the presence of binding sites in the 30 UTR. Of
the seven genes that overlapped among these algorithms (Fig-
ure 3A), we selected four genes (GON4L, HOXB3, NNAT, and
CNTFR) that were associated with metastasis-related functions
such as cell proliferation, apoptosis, cell cycle, migration, adhe-
sion, invasion, and cell differentiation (Figures S3A and S3B). We
also selected six genes (SSH2, EPDR1, SSRP1, HNRNPK,
YWAHZ, and USP9X) with prometastatic function that were
predicted by more than one algorithm (Figure S3A) and three
additional genes (CD44, ENAH, and NTRK2) that had multiple
binding sites predicted by an independent algorithm developed
in-house.
To establish a direct relationship between miR-708 and pre-
dicted target genes, we cloned the 30 UTR of key target genes
into a dual-luciferase UTR vector (Figure 3B). Notably, 30 UTR
of NNAT (which encodes neuronatin), GON4L, NTRK2, and
CD44 appeared to be repressed by miR-708 (Figure 3B).
However, at the protein level, of the genes tested, expression
of neuronatin protein was significantly decreased by miR-708
(Figure 3C), consistent with RT-PCR analysis (Figure S3C). We
also evaluated AKT2, which was recently reported to be a target
of miR-708 in primary prostate cancer (Saini et al., 2012), but did
not find it to be suppressed by miR-708 in breast cancer (data
not shown). Consistent with the constitutive expression system,
doxycycline-mediated acute and conditional expression of miR-
708 also suppressed neuronatin levels (Figure S3D). As would be
expected, there existed an inverse correlation between miR-708
and NNAT levels in MCF7 and MDA cells (Figures 1B and S3C).
Evaluation of the 30 UTR sequence of NNAT revealed one
binding site with perfect matches both in the seed and flankingsequences for miR-708 (Figures 3D and S3E). Notably, both
miR-708 and the binding site in the NNAT are highly conserved
across species (Figure S3F). We next generated mutations in
the binding site to abrogate miR-708-NNAT 30 UTR interaction
(Figure 3D). As expected, whereas a reporter with an intact
NNAT 30 UTR was effectively suppressed by miR-708, that
withNNAT 30 UTR carrying a mutated binding site was refractory
to suppression by miR-708 (Figure 3E). To determine if NNAT
with a 30 mutant UTR (NNAT-mut) was also refractory to miR-
708-mediated suppression, we expressed a cDNA that harbored
a mutation in the 30 UTR containing the miR-708 binding
sites. This mutant UTR abolished miR-708-mediated suppres-
sion of the NNAT (Figure 3F). Having established that miR-708
regulates NNAT expression, we next determined if there was
an inverse correlation between miR-708 and NNAT levels in
the breast cancer cell lines examined in Figure 1. Notably,
NNAT levels inversely correlated with miR-708 expression (Fig-
ure 3G). Taken together, these results indicate that miR-708
directly regulates NNAT expression through the perfect binding
site in the 30 UTR.
miR-708-Mediated Suppression of Neuronatin Impacts
the Release of Store-Operated Ca2+
Neuronatin is a membrane protein in the ER (Joseph et al., 1994)
that resembles phospholamban, an inhibitor of sarcoplasmic
reticulum Ca2+-ATPase (SERCA). Neuronatin-mediated regula-
tion of intracellular Ca2+ has been implicated in neural induction
in embryonic stem cells (Lin et al., 2010) and in adipogenesis
(Suh et al., 2005). Notably, Ca2+ is a critical regulator of cell
migration (Pettit and Fay, 1998; Yang et al., 2009). We therefore
hypothesized that miR-708-mediated targeting of NNAT may
lead to impaired regulation of intracellular Ca2+, which could
explain the inhibitory effect on the migratory phenotype of meta-
static tumor cells observed earlier (Figure 1E). To test this
hypothesis, we monitored the intracellular Ca2+ levels in MDA
and MDA expressing miR-708 (MDA-miR-708) cells in the
absence and presence of exogenous ATP. ATP binds ATP
receptors on the cell surface, resulting in the cleavage of PIP2
into IP3 and DAG. IP3 binds IP3 receptors on the ER membrane
and releases ionized calcium from the ER (Vandewalle et al.,
1994; Berridge et al., 2003; Swanson et al., 1998). Thus, ATP-
stimulated calcium release from ER was used to evaluate the
consequence of NNAT suppression by miR-708. As expected,
MDA cells responded to ATP by exhibiting a rapid increase of
Ca2+, followed by a regulatory phase back to basal levels (Fig-
ure 4A). In contrast, MDA-miR-708 cells exhibited a similar
Ca2+ transient but attenuated regulation of intracellular Ca2+,
indicating that NNAT knockdown by miR-708 may be respon-
sible for the aberrant Ca2+ reuptake mechanism to the ER (Fig-
ure 4A). To directly demonstrate that suppression of NNAT by
miR-708 was responsible for the decreased Ca2+ influx, we per-
formed a rescue experiment by expressingNNAT cDNAwith a 30
mutant UTR in MDA-miR-708 (MDA-miR-708-NNAT-mut) cells.
There were no differences in the basal intracellular Ca2+ levels
or peak response to ATP among the MDA control, MDA-miR-
708, and MDA-miR-708-NNAT-mut cells (Figure 4B). Strikingly,
expression of the NNAT-mut rescued the defects in intracellular
Ca2+ regulation in miR-708-expressing MDA cells (Figure 4C), as
well as themigration phenotype (Figure 4D). Notably, expressionCancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc. 67
Figure 3. miR-708 Regulates Expression of Neuronatin
(A) Venn diagrams showing the number of genes identified as potential targets of miR-708 as predicted by three algorithms: TargetScan, miRanda, and
TargetRank.
(B) A schematic of a dual-luciferase vector used for cloning 30 UTR of candidate genes. Dual-luciferase assays showing that repression of candidate genes by
miR-708 was measured as ratios of Renilla and Firefly luciferase activity in 293T cells. Data represent mean ± SD. *p < 0.01.
(C) Western blot analysis of endogenous candidate proteins in MDA (Control) and MDA-MB-231-miR-708 (MDA-miR-708) cells. b-Actin serves as an internal
control.
(D) Sequences of miR-708 and the potential miR-708 binding site at the 30 UTR of NNAT. Also shown are nucleotides mutated in NNAT-30 UTR mutant.
(E) Dual-luciferase assays showing repression of wild-type UTR (NNAT-UTR) or mutant UTR (NNAT-UTR-mut) following transfection of synthetic miR-708 or
scrambled (SCR) miRNA. Data represent mean ± SD.
(legend continued on next page)
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miR-708 Is a Suppressor of MetastasisofNNAT-mut alone in control MDA cells did not impact migration
rates (FiguresS4A–S4C). To directly demonstrate that the regula-
tion of Ca2+ is the main reason for miR-708-NNAT-mediated
migration phenotype, we used BAPTA-AM, an intracellular
calcium chelator (Hoth and Penner, 1992). As expected,
BAPTA-AMshowed a dramatic impairment inMDA cell migration
(Figures 4E, S4D, and S4E), whereas migration in MDA-miR708
cells remained less affected. More importantly, expression of
NNAT-mut in MDA-miR-708 cells rescued the BAPTA-AM-
induced cell migration defects. To exclude the possibility that
themigration effectswere not confined to theMDAcell line alone,
we used another metastatic cell line, MDA-MB-436. Consistent
with previous data, MDA-MB-436 cells expressing miR-708
also showed increased migration that remained less affected
by BAPTA-AM (Figure S4F) and decreased levels of NNAT (Fig-
ure S4G). These results suggest that suppression of miR-708 in
metastatic tumor cells is necessary for NNAT to maintain
adequate levels of intracellularCa2+ stores required for themigra-
tory phenotype. Furthermore, the demonstration that miR-708
regulates NNAT expression provides an insight into Ca2+ regula-
tion in metastatic tumor cells.
miR-708-Induced Aberrant Ca2+ Regulation Impacts
Focal Adhesion Kinase
To further elucidate the mechanisms by which the miR-708-
NNAT-Ca2+ axis regulates cell migration, we evaluated down-
stream signaling pathways. ATP-induced transient elevation of
intracellular Ca2+ has been shown to trigger key components
of numerous signaling pathways, including protein kinases
such as the calmodulin-dependent kinases (CaMKs) and the
extracellular signal-regulated kinases (ERKs) (Swanson et al.,
1998). Following Ca2+ release by ATP, MDA cells showed a rapid
and transient increase in phospho (p)-p44/ERK1 and p42/ERK2
over basal levels as compared with MDA-miR-708 cells (Figures
4F and S4H), suggesting that aberrant intracellular Ca2+ regula-
tion inMDA-miR-708 cells may be responsible for reduced levels
of activated ERK. Importantly, expression of mutant NNAT
rescued p-ERK levels in MDA-miR-708 cells (Figures 4F and
S4H). ERK has been implicated in the migration of numerous
cell types by virtue of its ability to phosphorylate several protein
kinases, including focal adhesion kinase (FAK) (Huang et al.,
2004). Indeed, fibroblasts derived from Fak knockout mice
show diminished migration ability (Ilic et al., 1995; Zhao and
Guan, 2009). In fact, elevated level of basal p-FAK (S910) was
observed in MDA compared to MDA-miR-708 cells (Figures 4F
and S4I). Notably, following ATP-mediated Ca2+ release, p-FAK
levels increased in MDA and not in MDA-miR-708 cells (Figures
4F and S4I). Again, as expected, expression of NNAT 30 mutant
UTR restored both the basal and ATP-induced p-FAK in MDA-
miR-708 cells (Figures 4F and S4I). These data are consistent
with previous reports showing that FAK phosphorylation at
S910 (Hunger-Glaser et al., 2004) is associated with increased
cell migration and metastasis (Zheng et al., 2009) and suggest(F) Western blot analysis showing neuronatin levels expressed from NNAT cDNA
synthetic miR-708 or scrambled (SCR) miRNA. b-Actin serves as an internal con
(G) Quantitative RT-PCR showing NNAT expression in a panel of nonmetastatic
See also Figure S3.that alleviated FAK activation may explain the attenuated migra-
tion attributes of miR-708-expressing cells. We next evaluated
focal adhesions at the cellular level by immunostaining for
vinculin, a well-known focal adhesion molecule, and p-FAK
(S910). Strikingly, p-FAK colocalized well with vinculin+ focal
adhesions in MDA and MDA-miR-708-NNAT 30 mutant UTR
cells, whereas the focal adhesions in MDA-miR-708 cells re-
mained devoid of p-FAK (Figure 4G). Furthermore, MDA-miR-
708 cells exhibited thick bands of cortical actin rings around
the cell’s periphery (Figure S4J), a phenotype previously associ-
ated with migration defects in FAK null cells (Sieg et al., 1999).
Taken together, these results suggest that miR-708-induced
aberrant Ca2+ levels are responsible for impacting ERK and
FAK activation. Importantly, expressing NNAT with a mutant 30
UTR that is refractory to miR-708 suppression in MCF7 cells
rescued aberrant Ca2+ levels and promoted cell migration (Fig-
ure S4K). These data are also in agreement with a previous study
showing that enhanced efflux of store-operated Ca2+ into the
cytoplasm is critical for serum-induced breast cancer cell migra-
tion via induction of FAK (Yang et al., 2009).
PRC2 Is Involved in the Suppression of miR-708
in Metastatic Cells
In a previous study, chromatin immunoprecipitation and deep-
sequencing (ChIP-seq) analysis of embryonic stem cells unrav-
eled several miRNAs, including miR-708, regulated by the PcG
repressor complex subunit SUZ12 (Marson et al., 2008). Consis-
tent with this observation, genome-wide profiling of chromatin
signatures in colorectal cancer revealed that miRNAs were
also epigenetically regulated (Suzuki et al., 2011). These obser-
vations suggested that the PcG group of transcriptional repres-
sors might suppress miR-708 in breast cancer metastasis.
Two distinct PcG complexes, polycomb repressor complex 1
(PRC1) and PRC2, are critical to maintaining a repressed gene
state (Schwartz and Pirrotta, 2007; Margueron et al., 2009;
Simon and Kingston, 2009), and PRC2, which includes SUZ12
and the catalytic subunit EZH2, is responsible for di- and trime-
thylation of lysine 27 on histone H3 resulting in gene repression
(Boyer et al., 2006; Cao et al., 2002; Koyanagi et al., 2005)
(Cao and Zhang, 2004).
Western blot analysis of breast cancer cells showed upregula-
tion of SUZ12 (approximately 7.5-fold) in metastatic MDA cells
compared with controls (Figure 5A), consistent with observa-
tions in metastatic prostate and breast cancer (Bracken et al.,
2009; Kleer et al., 2003; Sellers and Loda, 2002). To determine
whether the miR-708 promoter associates with the PcG com-
plex, we performed ChIP experiments for SUZ12 using cross-
linked chromatin from nonmetastatic and metastatic breast
cancer cells. The enriched DNA from the immunoprecipitates
(IPs) was quantified by RT-PCR using primers spanning the
miR-708 upstream regions (Figure 5B). Enrichment of SUZ12
was found to be associated with the miR-708 upstream region
in metastatic MDA and LM2 cells compared with nonmetastaticwith a wild-type UTR (NNAT) or mutant UTR (NNAT-mut) in the presence of
trol.
and metastatic breast cancer cells. Data represent mean ± SD.
Cancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc. 69
Figure 4. miR-708-Mediated Suppression of Neuronatin Results in Aberrant Ca2+ Regulation and Inactivation of ERK and FAK
(A) Representative calcium traces of MDA control (left panel) and MDA-MB-231-miR-708 cells (right panel) stimulated with ATP. The dotted lines represent the
initial rate of calcium regulation back to baseline.
(B) Peak calcium responses due to ATP stimulation (MDA control, MDA-miR-708, MDA-miR-708-NNAT-mut, respectively; 1.61 ± 0.04, 1.77 ± 0.06, 1.84 ± 0.05).
For ratios pre-ATP stimulation (basal), values are 1.00 ± 0.01, 0.97 ± 0.01, and 0.93 ± 0.02, respectively (n = 115, 107, and 72 cells, respectively). Transfection
efficiency in MDA-miR-708-NNAT-mut cells was 30%. Data are represented as mean ± SEM.
(legend continued on next page)
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Figure 5. PRC2 Suppresses miR-708
Expression in Metastatic Tumor Cells
(A) Western blot showing SUZ12 levels in non-
tumorigenic (MCF10A), nonmetastatic (MCF7),
and metastatic (MDA) breast cancer cells. b-Actin
serves as an internal control. A 7.5-fold change
was observed in MDA compared to MCF7.
(B) Schematic showing genomic location of miR-
708. The upstream regions used for ChIP-PCR are
indicated as short black lines.
(C) ChIP-PCR showing percent (%) input of SUZ12
at indicated locations upstream of miR-708 in
nontumorigenic breast cells (MCF10A), tumori-
genic and nonmetastatic breast cancer cells
(MCF7), and metastatic breast cancer cells (MDA,
LM2). A 5-fold change was observed in MDA
compared toMCF7. IgGwas used as control. Data
are representative of three independent experi-
ments (mean ± SD).
(D) ChIP-PCR showing percent (%) input of
H3K27me3 at indicated locations upstream of
miR-708 in nontumorigenic breast cells (MCF10A),
tumorigenic and nonmetastatic breast cancer
cells (MCF7), and metastatic breast cancer cells
(MDA, LM2). A 9-fold change was observed in
MDA compared to MCF7. Data are representative
of three independent experiments (mean ± SD).
(E) Effect of siRNA knockdown of SUZ12 (left
panel) on miR-708 expression (middle panel) and
H3K27me3 (right panel) in metastatic MDA cells.
Data represent mean ± SD.
See also Figure S5.
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miR-708 Is a Suppressor of Metastasiscells MCF10A and MCF7 (Figure 5C). No enrichment was de-
tected with an isotype-matched IgG antibody. As expected
from this regulated SUZ12 binding, H3K27 trimethylation in the
miR-708 region was strongly enhanced in the metastatic cells,
but not in the nonmetastatic cells (Figure 5D). As a control,(C) Initial rate of calcium regulation back to baseline. Data are represented as mean ± SEM (values for MDA
mut, respectively, 0.52 ± 0.03, 0.33 ± 0.02, and 0.56 ± 0.05 with n = 115, 105, and 72 cells).
(D) Transwell cell migration assay in NNAT 30 mutant UTR (MDA-miR-708-NNAT-mut) and miR-708 express
Data represent the mean ± SD of six randomly selected areas from two independent experiments.
(E) Quantification of cell migration as percentage of wound healed performedwith 13 106MDAcontrol, MDA-m
in the presence of Ca2+ inhibitor or BAPTA-AM at 24 hr. For each cell line, cell migration is normalized to no
randomly selected areas from three independent experiments.
(F) Western blots showing levels of p-ERK (T202) and p-FAK (S910) following stimulation with ATP (0 and 5 m
NNAT-mut cells. b-Actin serves as an internal control.
(G) Immunostaining of MDA control, MDA-miR-708, and MDA-miR-708-NNAT-mut cells for colocalization
indicate focal adhesions. Scale bars, 20 mm.
See also Figure S4.
Cancer Cell 23, 63–7SUZ12 target promoters MYOD1 and
SAT2 (known targets of heterochro-
matin-associated H3K27me3) were effi-
ciently pulled down with H3K27me3
antibody compared to GAPDH and
ACTB (Figures S5A and S5B). These
data suggest that SUZ12 interaction
with the miR-708 promoter may result in
the suppression of miR-708.
To further demonstrate that the PRC2
activity is directly responsible for miR-708 silencing, we performed siRNA-mediated knockdown of
PRC2 subunit SUZ12. Strikingly, SUZ12 knockdown restored
expression of miR-708 in metastatic MDA breast cancer cells
(Figures 5E, S5C, and S5D). Similar results were obtained with
another metastatic breast cancer cell line, MDA-MB-436control, MDA-miR-708, and MDA-miR-708-NNAT-
ing MDA (MDA-miR-708) cells. Scale bars, 50 mm.
iR-708, andMDA-miR-708-NNAT-mut cells either
BAPTA control. Data represent mean ± SD of nine
in) in MDA control, MDA-708, and MDA-miR-708-
of vinculin and p-FAK in focal adhesions. Arrows
6, January 14, 2013 ª2013 Elsevier Inc. 71
Figure 6. In Situ Hybridization Analysis
Shows Reduced miR-708 Levels in Metas-
tases of Patients with Breast Cancer
(A) Representative images showingmiR-708 in situ
hybridization (ISH) (red) in human primary breast
tumors (Primary tumor) and matched lymph node
metastases (LN Met, upper panel) and control U6
in situ hybridization (lower panel). Scale bars,
50 mm.
(B) Quantitation of miR-708 expression and
control U6 expression in human primary breast
tumors (Primary, n = 6) and matched lymph node
metastasis (Metastases, n = 6). Data represent
mean ± SD.
(C) Representative images showing miR-708
in situ hybridization (red) in lung metastases (Lung
Met, upper panel) and human normal lungs
(Normal lung, lower panel) and control U6 in situ
hybridization. Scale bars, 50 mm.
(D) Quantitation of miR-708 expression and U6
expression in normal lungs (Normal) and lungs
from patients with breast cancer with metastases
(metastases, n = 10 sections each, two indepen-
dent cases). Data represent mean ± SD.
See also Table S5 and Figure S6.
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miR-708 Is a Suppressor of Metastasis(Figure S5E). As expected, upregulation of miR-708 expression
following SUZ12 knockdown resulted in decreased NNAT
expression (Figure S5F). Similarly, suppression of EZH2, another
key subunit of the PRC2, also restored expression of miR-708 in
metastatic MDA breast cancer cells (Figures S5G and S5H).
We next determined if the PRC2-induced H3K27 trimethyla-
tion was the cause of miR-708 suppression. Indeed, SUZ12
knockdown resulted in decreased levels of H3K27me3 on the
miR-708 upstream region (Figure 5E). These data establish that
the PRC2mediates suppression of miR-708 in metastatic breast
cancer cells. To determine if the PRC2-miR-708 axis was also
involved in metastasis in vivo, we examined the MMTV-PyMT
breast cancer model. Evaluation of primary mammary tumors
and matched lung metastases from these mice showed an
inverse correlation between Suz12 and miR-708 expression
(Figures S5I, S1D, and S1E). To establish a direct connection
between SUZ12 and miR-708 in the MMTV-PyMT model, we
evaluated cell lines derived from MMTV-PyMT tumors (meta-
static and nonmetastatic variants) (Borowsky et al., 2005).72 Cancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc.Increased miR-708 expression associ-
ated with Nnat suppression was ob-
served in nonmetastatic MMTV-DB7 cells
compared to the metastatic variant
MMTV-Met1 (Figures S5J and S5K), con-
sistent with observations in human
breast cancer cells. As expected, siRNA-
mediated knockdown of Suz12 relieved
repression of miR-708 and decreased
Nnat levels in metastatic MMTV-Met1
cells (Figures S5L and S5M). Although
there is a possibility that a repressor or
a loss of a transactivator may be involved,
our human and murine studies suggest
that PRC2-induced H3K27 trimethylationcontributes to the regulation ofmiR-708 expression inmetastatic
cancer cells.
miR-708 Expression Is Suppressed in Both Lymph Node
and Distal Metastases in Patients with Breast Cancer
Next, we asked whether metastatic lesions in patients with
breast cancer exhibit attenuated levels of miR-708, as observed
in human breast cancer cell models and in mouse models of
breast cancer that metastasizes to the lung.We analyzed a panel
of frozen human primary breast tumors and matched lymph
node metastases by in situ hybridization for miR-708 expression
(Table S5). Strikingly, compared to primary breast tumors, miR-
708 expression level was significantly reduced inmatched lymph
node metastases, whereas control U6 snRNA expression levels
remained unchanged (Figures 6A, 6B, and S6A). We expanded
this analysis by quantitated miR-708 levels in formalin-fixed
paraffin-embedded (FFPE) samples using TaqMan qPCR (Table
S5). Consistent with the in situ hybridization data, suppression of
miR-708 was observed in metastases compared to primary
Figure 7. Neuronatin with a Mutant 30 UTR
Rescues miR-708-Mediated Metastasis
Suppression In Vivo
(A) Representative bioluminescence (BLI) images
of animals showing primary tumors derived from
orthotopic injections of control MDA cells (Ctrl),
MDA-miR-708 (miR-708) cells, and MDA-miR-
708-NNAT-mut (miR-708-NNAT-mut) cells into the
mammary fat pad. The color scale bar depicts the
photon flux (photons per second) emitted from
these mice at day 30.
(B) Quantitation of primary tumors as assessed by
BLI measurements as a function of time (in weeks,
n = 10 per group). Data represent mean ± SD.
(C) Representative BLI of animals from (A) showing
lung metastases at day 37. Primary tumors were
resected at day 30. The color scale bar depicts the
photon flux (photons per second) emitted from
these mice.
(D) Quantitation of pulmonary metastases as as-
sessed by BLI measurements (day 37, n = 10 per
group). Data represent mean ± SD.
(E) Number of metastatic nodules in the lungs
of mice derived from primary tumors shown in (A)
(ten lungs from each group, five to six sections
evaluated per lung). Data represent mean ± SD.
(F) Representative H&E of lungs showing meta-
static nodules. Scale bars, 50 mm.
(G) Number of CTCs in the peripheral blood of
mice-bearing control LM2 (Control) cells and
MDA-MB-231-LM2-miR-708 (miR-708) orthotopic
tumors expressing GFP transgene. qPCR for GFP
was used to determine CTC abundance in the
peripheral blood. CTC numbers were determined
by generating a standard curve with a pre-
determined number of control cells spiked into the
mouse blood. Data represent mean ± SD.
See also Figure S7.
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miR-708 Is a Suppressor of Metastasistumors (Figures S6C–S6E). Similarly, analysis of miR-708 ex-
pression in distal lung metastases in patients with breast cancer
showed a dramatic reduction inmiR-708 expression (Figures 6C,
6D, and S6B). We also evaluated NNAT expression in samples
from patients with breast cancer (Table S5). As expected,
NNAT expression inversely correlated with miR-708 expression
in primary tumor and matched metastatic tissue (Figure S6F).
Having demonstrated that ectopic expression of NNAT-mut
rescued miR-708 phenotypes pertaining to cell migration
in vitro, we next determined whether NNAT would also rescue
metastasis in vivo. We injected MDA control (or LM2 control),
MDA-miR-708 (or LM2-miR-708), and MDA-miR-708-NNAT-
mut (or LM2-miR-708-NNAT-mut) cells orthotopically in the
mammary gland of SCID mice and allowed development of
lung metastases. As expected, there was no change in primary
tumor growth as determined by BLI (Figures 7A and 7B) and
tumor size measurements (Figure S7). However, metastases
were suppressed in MDA-miR-708, and importantly, expressing
NNAT-mut rescued metastasis defects of MDA-miR-708 in vivo
(Figures 7C and 7D). As expected, IHC analysis showed reduced
number of lung metastatic nodules in LM2-miR-708 compared
to controls (Figures 7E and 7F). Consistent with these observa-
tions, LM2-miR-708 tumor-bearing mice showed reduced
number of circulating tumor cells (CTCs) compared to controls(Figure 7G), suggesting the possibility that miR-708-mediated
inhibition of cell migrationmay have caused reduction in dissem-
inated CTCs. These observations together with clinical data from
patients with breast cancer showing marked suppression of
miR-708 in both lymph node metastases and distal metastases
compared to matched primary tumors provide a compelling
rationale for developing miR-708 as a therapeutic agent against
breast cancer metastasis. Given that miR-708 is a relatively
unexplored miRNA, not much information is available in public
databases about its expression and patient survival. Future
studies are required to expand the analysis of miR-708 in meta-
static lesions to a larger cohort of patients with breast cancer to
determine with statistical confidence whether reduced levels of
miR-708 correlate with worst patient outcome.
EXPERIMENTAL PROCEDURES
miRNA Library Construction, Deep Sequencing, and Data Analysis
Total RNA extraction, library construction, and high-throughput sequencing
were performed as described (Ryu et al., 2011). Additional information is avail-
able in Supplemental Experimental Procedures.
Human Samples
Human tumor samples were collected from patients enrolled on institutional
review board-approved trials at Weill Cornell Medical College and ColumbiaCancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc. 73
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miR-708 Is a Suppressor of MetastasisUniversity College of Physicians and Surgeons (New York) conducted
between 1995 and 2010. Specimens were collected after obtaining written
informed consent prior to undergoing any study-specific procedures in accor-
dance with the Declaration of Helsinki. Patient’s identity of pathological spec-
imens remained anonymous in the context of this study.
Generation of miRNA and miRNA ‘‘Sponge’’ in Lentiviral Constructs,
Virus Generation, and Transduction
To express miRNA-708 in cells, 500 bp of pri-miRNA containing the mature
miR-708 sequence 50-AAGGAGCUUACAAUCUAGCUGGG-30 was amplified
and cloned into the pZEO lentiviral construct in fusion with a GFP reporter
as described (Ryu et al., 2011). miRNA sponge was generated as described
by Ebert et al. (2007). Briefly, the sponge contains 12 miR-708 binding sites,
50-CCCAGCTAGATCATAGCTCCTT-30, fused with GFP and driven by an
EF1a promoter. Additional constructs and cloning methods are available in
Supplemental Experimental Procedures.
Mouse Pulmonary Metastasis Models
All animal work was conducted in accordance with a protocol approved by the
Institutional Animal Care and Use Committee at Weill Cornell Medical College.
For orthotopic injection, 1 3 106 viable MDA control, or MDA-miR-708 cells
were injected into CB-17 SCID mice fat pads in a volume of 0.1 ml. Tumor
growth and pulmonary metastases (following resection of primary tumor)
were monitored by live animal BLI (Xenogen IVIS system) once per week.
Intracellular Calcium Measurements
MDA control, MDA-miR-708, and MDA-miR-708-NNAT-mut cells were grown
on coverslips for 2–3 days and then loaded with 10 mM Fura-2 (Molecular
Probes), a membrane-permeable Ca2+-indicator dye, at 37C for 30 min. Cells
were processed and attached to the bottom of a flowthrough superfusion
chamber and mounted on the stage of an inverted epifluorescence micro-
scope (Nikon Eclipse TE-2000). The cells in the chamber were superfused
and maintained at 37C as previously described (O’Connor and Silver,
2007). Additional information is available in Supplemental Experimental
Procedures.
In Situ Hybridization with miR-708 LNA Probes
Tissue sections were obtained from primary human breast tumor andmatched
lymph node metastases, as well as from spontaneous primary breast tumors
and matched lung metastases harvested from mice (MMTV-PyMT;WAP-Cre;
CAG-CAT-EGFP, 15 weeks). Sections were treated and hybridized with
DIG-labeled miR-708 or U6 LNA probes (Exiqon, Woburn, MA, USA) overnight
at 30C. Sections were processed further and incubated with anti-DIG Ab-
POD, Fab fragments (Roche, IN, USA) overnight at 4C.
To quantify miRNA from FFPE specimens, we isolated total RNA including
small RNA using miRNeasy FFPE kit (QIAGEN) and quantified miRNA using
TaqMan microRNA Assays (Applied Biosystems, CA, USA). RNU48 (Applied
Biosystems) was used for normalization. Additional details are available in
Supplemental Experimental Procedures.
ChIPs
ChIP assays were performed using the EZ-CHIP chromatin immunoprecipita-
tion Kit (Millipore, CA, USA) following the manufacturer’s protocol. IP
complexes were immunoprecipitated with a SUZ12 antibody (Abcam; catalog
#12073) and an anti-histone H3K27me3 antibody (Millipore; catalog #07-449)
overnight at 4C. Mouse IgG (negative control; Millipore, catalog #12-371B)
and RNA PolII (positive control; Millipore, catalog #05-623B) were used as
controls. The contents of each specific DNA locus were amplified by real-
time PCR (iQ SYBR Green Supermix; Bio-Rad) using four different locations
upstream of miR-708. Amplification efficiency was calculated, and the data
were expressed as enrichment related to input. Additional details are available
in Supplemental Experimental Procedures.
Statistical Analysis
Results are expressed as mean ± SD. Analyses of different treatment groups
were performed using the nonparametric Mann-Whitney U t test using the
GraphPad Prism statistical program. The p values <0.05 were considered
significant. Error bars depict SD, except where indicated otherwise.74 Cancer Cell 23, 63–76, January 14, 2013 ª2013 Elsevier Inc.ACCESSION NUMBERS
Deep-sequencing data have been deposited in GEO with accession number
GSE42313.
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